Si Qiu

Title: Si Qiu: Innovator in Tumor Antigen Research

Introduction

Si Qiu is a prominent inventor based in Guangdong, China. He has made significant contributions to the field of cancer research through his innovative work on tumor antigens. His research focuses on developing novel therapeutic approaches for cancer diagnosis, prevention, and treatment.

Latest Patents

Si Qiu holds a patent for a Col14A1-derived tumor antigen polypeptide and its applications. This patent includes a tumor antigen polypeptide with a specific amino acid sequence, as well as a nucleic acid encoding the polypeptide. The patent also covers a nucleic acid construct, an expression vector, and a host cell that incorporates the encoding nucleic acid. Additionally, it describes an antigen presenting cell that displays the tumor antigen polypeptide on its surface, along with an immune effector cell. The applications of this invention are crucial for advancing cancer diagnostics and therapies.

Career Highlights

Si Qiu is associated with Genoimmune Therapeutics Co., Ltd., where he continues to push the boundaries of cancer research. His work is characterized by a commitment to developing innovative solutions that can significantly impact patient outcomes.

Collaborations

Si Qiu collaborates with notable colleagues, including Bo Li and Geng Liu. Their combined expertise enhances the research efforts at Genoimmune Therapeutics Co., Ltd.

Conclusion

Si Qiu's contributions to tumor antigen research exemplify the importance of innovation in the fight against cancer. His patent and ongoing work hold promise for improving cancer diagnosis and treatment options.